一種治療慢性阻塞性肺病的新版支氣管擴張劑，設計使用非氯氟烴推進劑類的氫氟酸做為推進劑，這是對《蒙特利爾方案》的響應，該方案是保護臭氧層的全球性協議。

新版本叫做Atrovent HFA(異丙托溴銨氫氟酸)，設計用來替代支氣管痙攣（包括慢性支氣管炎和肺氣腫）維持治療的Atrovent CFC吸入氣霧劑。新版是由Boehringer Ingelheim公司研制開發。一項為期12周雙盲、安慰劑對照、活動控制臨床試驗已經確立，是為了比較Atrovent HFA與Atrovent CFC的安全性與有效性。兩種產品都很安全有效，沒有統計學的顯著差異。

有異丙托溴銨過敏史的患者禁忌使用Atrovent HFA，當需要緊急治療的時候可以做為急性支氣管痙攣的初始治療。Atrovent HFA已經獲得了美國食品藥品管理局的許可。

Boehringer Ingelheim制藥公司臨床與科學事務部治療主任Steven Kersten醫生說：“這個許可與我們公司的承諾保持了一致，即研究與開發CFC為基礎的吸入劑的替代產品?！?
 
Environmentally Safe COPD Drug
 
A new version of a bronchodilator for treating patients with chronic obstructive pulmonary disease (COPD) is formulated with a non-chlorofluorocarbon (CFC) propellant called hydrofluoroalkane (HFA), in response to the Montreal Protocol, a global agreement to protect the ozone layer.

This new version, called Atrovent HFA (ipratropium bromide HFA), is designed to replace Atrovent CFC inhalation aerosol for maintenance treatment of bronchospasm, including chronic bronchitis and emphysema. The new version was developed by Boehringer Ingelheim (Ingelheim, Germany; www.boehringer-ingelheim.com). A 12-week, double-blind, placebo, and active-controlled trial has established the comparable safety and efficacy of Atrovent HFA to Atrovent CFC. Both products were shown to be safe and effective with no statistically significant differences between them.

Atrovent HFA is contraindicated in patients with a history of hypersensitivity to ipratropium bromide and for the initial treatment of acute episodes of bronchospasm where rapid response is required. Atrovent HFA has been cleared by the U.S. Food and Drug Administration (FDA).

“This approval is in keeping with our commitment to the research and development of replacements to our CFC-based inhalers,” commented Steven Kersten, M.D., therapeutic director in clinical and scientific affairs for Boehringer Ingelheim Pharmaceuticals.